NCT02968420View on ClinicalTrials.gov

Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Human Papillomavirus
Interventions
BIOLOGICAL

Human Papillomavirus 9-valent Vaccine, Recombinant

All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.

Trial Locations (1)

V5Z 4H4

Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver

All Listed Sponsors
collaborator

Merck Canada Inc.

INDUSTRY

lead

University of British Columbia

OTHER

NCT02968420 - Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine | Biotech Hunter | Biotech Hunter